Swainsonine
| Names | |
|---|---|
| Preferred IUPAC name (1S,2R,8R,8aR)-Octahydroindolizine-1,2,8-triol | |
| Other names Tridolgosir | |
| Identifiers | |
| 3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.123.531 | 
| KEGG | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| 
 | |
| 
 | |
| Properties | |
| C8H15NO3 | |
| Molar mass | 173.2 | 
| Melting point | 143 to 144 °C (289 to 291 °F; 416 to 417 K) | 
| 10 mg/1 mL | |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references | |
Swainsonine is an indolizidine alkaloid. It is a potent inhibitor of Golgi alpha-mannosidase II, an immunomodulator, and a potential chemotherapy drug. As a toxin in locoweed (likely its primary toxin) it also is a significant cause of economic losses in livestock industries, particularly in North America. It was first isolated from Swainsona canescens.